Mårten Ferná

List of Publications by Year
in descending order

47 papers	1,720 citations	331259 21 h-index	288905 40 g-index
49 all docs	49 docs citations	49 times ranked	3312 citing authors

#	Article	IF	Citations
1	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. British Journal of Cancer, 2022, 126, 1145-1156.	2.9	20
2	Abstract PD9-05: Prognostic and tamoxifen-predictive effect of PAM50 and ROR score in premenopausal women included in the randomised SBII:2 trial. Cancer Research, 2022, 82, PD9-05-PD9-05.	0.4	0
3	The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer. Cancers, 2022, 14, 941.	1.7	5
4	PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients. Npj Breast Cancer, 2022, 8, 61.	2.3	5
5	Abstract PS5-09: Tumour infiltrating lymphocytes of prognostic value in different molecular breast cancer subgroups and as a suggestive predictive factor for adjuvant tamoxifen benefit in premenopausal patients after 30 years follow-up. , 2021, , .		0
6	Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. Breast Cancer Research and Treatment, 2021, 187, 45-55.	1.1	8
7	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer. Npj Breast Cancer, 2021, 7, 127.	2.3	9
8	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 2021, 154, 128-137.	1.3	24
9	The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breastâ€"Long-Term Prognostic Significance. Cells, 2020, 9, 1718.	1.8	10
10	Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breastâ€conserving surgery: a longâ€term followâ€up of the SweBCG91â€RT randomised trial. Molecular Oncology, 2020, 14, 2713-2726.	2.1	2
11	Co-localization of CD169 ⁺ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. OncoImmunology, 2020, 9, 1848067.	2.1	9
12	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Clinical Cancer Research, 2020, 26, 171-182.	3.2	14
13	Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. PLoS ONE, 2020, 15, e0231786.	1.1	15
14	Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. Breast Cancer Research and Treatment, 2020, 181, 369-381.	1.1	25
15	Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Research, 2020, 22, 140.	2.2	25
16	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	1.1	23
17	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	1.2	75
18	The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment, 2019, 175, 305-316.	1.1	8

#	Article	IF	Citations
19	Assessment of early response biomarkers in relation to longâ€term survival in patients with HER2â€negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer, 2018, 142, 618-628.	2.3	27
20	Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment. OncoImmunology, 2018, 7, e1408751.	2.1	64
21	Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer. BMC Cancer, 2018, 18, 1226.	1.1	3
22	Stability of oestrogen and progesterone receptor antigenicity in formalinâ€fixed paraffinâ€embedded breast cancer tissue over time. Apmis, 2018, 126, 746-754.	0.9	4
23	Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Research, 2018, 20, 64.	2.2	40
24	Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy.. Journal of Clinical Oncology, 2018, 36, 535-535.	0.8	1
25	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	3.2	17
26	Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta OncolÃ³gica, 2017, 56, 68-74.	0.8	51
27	Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 3222-3229.	0.8	74
28	Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS ONE, 2017, 12, e0179775.	1.1	8
29	Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial. Journal of Clinical Oncology, 2016, 34, 2232-2238.	0.8	30
30	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasisâ€"Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 146-157.	3.2	38
31	Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE, 2016, 11, e0150977.	1.1	9
32	Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status. PLoS ONE, 2015, 10, e0134932.	1.1	7
33	Serial monitoring of circulating tumor <scp>DNA</scp> in patients with primary breast cancer for detection of occult metastatic disease. EMBO Molecular Medicine, 2015, 7, 1034-1047.	3.3	380
34	Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent. Journal of Clinical Pathology, 2015, 68, 1012-1019.	1.0	15
35	Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. European Journal of Cancer, 2015, 51, 2304-2313.	1.3	8
36	A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma. European Urology, 2015, 68, 824-832.	0.9	111

#	Article	IF	Citations
37	Loss of TGFÎ² Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance. Cancer Research, 2015, 75, 1457-1469.	0.4	26
38	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Research, 2015, 17, 102.	2.2	30
39	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget, 2015, 6, 33306-33318.	0.8	31
40	The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRÎ±, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e102176.	1.1	49
41	Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus, 2014, 3, 70.	1.2	14
42	Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors11Grant support: The Swedish Cancer Society, the Swedish research council, the Nilsson Cancer foundation, the BioCARE Strategic Cancer Research program, the Lund Medical Faculty, and FoU Landstinget Kronoberg and SÃ¶dra RegionvÃ¥rdnÃ¤mnden.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 791-797.	0.8	106
43	Claudinâ€2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Molecular Oncology, 2014, 8, 119-128.	2.1	61
44	Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer. Journal of Clinical Oncology, 2005, 23, 4695-4704.	0.8	80
45	Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. European Journal of Cancer, 2005, 41, 256-264.	1.3	92
46	Correlation between estrogen receptor Î± expression, collagen content and stiffness in human uterine arteries. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 610-615.	1.3	7
47	Estrogen and progesterone receptors in vessel walls: Biochemical and immunochemical assays. Acta Obstetricia Et Gynecologica Scandinavica, 1993, 72, 10-16.	1.3	57